Anti-osteoporotic treatments in France: initiation, persistence and switches over 6 years of follow-up
详细信息 查看全文
- 作者：M. Belhassen ; C. B. Confavreux ; B. Cortet ; L. Lamezec…
- 关键词：First ; line treatment ; France ; Medical care ; Osteoporosis ; Persistence ; Switch
- 刊名：Osteoporosis International
- 出版年：2017
- 出版时间：March 2017
- 年：2017
- 卷：28
- 期：3
- 页码：853-862
- 全文大小：
- 刊物类别：Medicine
- 刊物主题：Orthopedics; Endocrinology; Rheumatology;
- 出版者：Springer London
- ISSN：1433-2965
- 卷排序：28
文摘
SummaryLimited information is available on anti-osteoporotic treatment initiation patterns in France. In 2006–2013, the most frequently prescribed first-line treatment class for osteoporosis was represented by bisphosphonates (alendronic acid and risedronic acid), followed by strontium ranelate. Persistence with anti-osteoporotic treatment was low, with high proportions of treatment discontinuations and switches.